CLINICAL RESPONSE TO MEDICATIONS FOR NEUROPSYCHIATRIC DISEASES: CLINICAL EXOME PANEL (Sec. & CNVs) – 8 genes
Delivery time
3-4 weeks
Sample
Blood
The neuropsychiatric drug response panel studies genetic variants that influence the metabolism, efficacy, and risk of adverse reactions to drugs used in psychiatry and neurology. It includes cytochrome P450 genes (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4) and HLA system alleles (HLA-A31:01, HLA-B15:02, HLA-B*15:11) associated with severe hypersensitivity to certain antiepileptic drugs (carbamazepine, oxcarbazepine, lamotrigine). This study guides the selection and dosage of antidepressants (amitriptyline, citalopram, fluoxetine, venlafaxine), antipsychotics (haloperidol, quetiapine, risperidone, aripiprazole), anxiolytics and antiepileptics, reducing the likelihood of adverse effects or lack of therapeutic response.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€